Zobrazeno 1 - 10
of 151
pro vyhledávání: '"Unal, Egeli"'
Publikováno v:
Cancer Biology & Therapy, Vol 25, Iss 1 (2024)
ABSTRACTRedox adaptation causes poor prognosis by adapting cancer cells to excessive oxidative stress. Previously, we introduced an oxidative stress-resistant metastatic prostate cancer (mPC) model (LNCaP-HPR) that redox adaptation reduced the effect
Externí odkaz:
https://doaj.org/article/aca243f93c564fef92f744ce9d28946b
Autor:
Havva Tezcan Unlu, Furkan Saridas, Ozlem Taskapilioglu, Gulsah Cecener, Unal Egeli, Omer Faruk Turan, Berrin Tunca, Mehmet Zarifoglu
Publikováno v:
Neurological Sciences and Neurophysiology, Vol 40, Iss 2, Pp 81-87 (2023)
Introduction: Recent research into multiple sclerosis (MS) has focused on the role of microRNAs (miRNAs) in the development of the disease. This study was designed to analyze miR-146a expression in whole blood and fecal samples of patients with MS. T
Externí odkaz:
https://doaj.org/article/f52e3ad439b74d22b5e615a8bb4914f1
Correlation between Ubiquitin E3 Ligases (SIAHs) and Heat Shock Protein 90 in Breast Cancer Patients
Autor:
Leila Sabour Takanlou, Gulsah Cecener, Maryam Sabour Takanlou, Hulya Ozturk Nazlioglu, Havva Tezcan Unlu, Ozgen Isik, Unal Egeli, Berrin Tunca, Erdem Cubukcu, Sahsine Tolunay, Mustafa Sehsuvar Gokgoz
Publikováno v:
Iranian Journal of Public Health, Vol 51, Iss 8 (2022)
Background: Breast cancer is a heterogeneous disease and differences in the expression levels of the ER, PR, and HER2 the triplet of established biomarkers used for clinical decision-making have been reported among breast cancer patients. Furthermore
Externí odkaz:
https://doaj.org/article/a7e0c5d247564e079a36c1c42e000b3d
Autor:
Omer Gokay Argadal, Melis Mutlu, Secil Ak Aksoy, Hasan Kocaeli, Berrin Tunca, Muhammet Nafi Civan, Unal Egeli, Gulsah Cecener, Ahmet Bekar, Mevlut Ozgur Taskapilioglu, Cagla Tekin, Gulcin Tezcan, Sahsine Tolunay
Publikováno v:
Biomolecules & Biomedicine, Vol 20, Iss 1 (2020)
Primary glioblastoma (GB) is the most aggressive type of brain tumors. While mutations in isocitrate dehydrogenase (IDH) genes are frequent in secondary GBs and correlate with a better prognosis, most primary GBs are IDH wild-type. Recent studies hav
Externí odkaz:
https://doaj.org/article/c58fd194674d45f3a11d086ac335a20d
Publikováno v:
Clinical and Experimental Pharmacology and Physiology. 49:1094-1104
Little is known about the redox-adapted cancer cells for understanding their pharmacologically targetable features and chemotherapeutic responses. Thus, we present the first in vitro redox adaptation model for metastatic prostate cancer (mPC), LNCaP-
Autor:
Isil Ezgi Eryilmaz, Berna Aytac Vuruskan, Onur Kaygısız, Gulsah Cecener, Unal Egeli, Hakan Vuruskan
Publikováno v:
Journal of Environmental Pathology, Toxicology and Oncology.
Publikováno v:
Journal of Cancer Research and Therapeutics. 19
Autor:
Furkan Sarıdaş, Mehmet Zarifoglu, Havva Tezcan Unlu, Gulsah Cecener, Unal Egeli, Ömer Faruk Turan, Berrin Tunca, Maryam Sabour Takanlou, Leila Sabour Takanlou, Ozlem Taskapilioglu
Publikováno v:
Neurological Research. 44:217-223
Multiple sclerosis (MS) is an inflammatory, autoimmune demyelinating, and neurodegenerative disorder of the central nervous system. Interactions between environmental factors, predisposition genes, and determining genes appear to be involved in its e
Autor:
Gulsah Cecener, Ersin Ozturk, Unal Egeli, Erdem Cubukcu, Berrin Tunca, Tuncay Yilmazlar, Ozkan Kanat, Secil Ak Aksoy, Turkkan Evrensel, Gulcin Tezcan, Adem Alemdar, Adem Deligonul
Publikováno v:
Genetic Testing and Molecular Biomarkers. 25:276-283
Background and Aim: In 10–30% of colorectal cancer (CRC) patients, toxic reactions occur after fluoropyrimidine-based chemotherapy. A dihydropyridine dehydrogenase (DPYD) gene variant, c.1905 + 1G>...
Autor:
Gulsah Cecener, Isil Ezgi Eryilmaz, Unal Egeli, Berrin Tunca, Beste Yurdacan, Dilara Kamer Colak, Mustafa Bakar
Publikováno v:
Alzheimer Disease & Associated Disorders. 35:214-222
INTRODUCTION Early-onset Alzheimer disease (EOAD) is an earlier Alzheimer disease form which is characterized by the mutations in the amyloid precursor protein, presenilin-1/2 (PSEN1/2), and triggering receptor expressed on myeloid cells 2 (TREM2). H